MIEP方案治疗复发或难治非霍奇金淋巴瘤疗效报告

目的　观察MIEP化疗方案治疗复发或难治非霍奇金淋巴瘤 (NHL)临床疗效和毒副作用。方法　 3 5例复发或难治NHL患者给予米托蒽醌 (MIT) 10mg/m2 静滴 ,d1;异环磷酰胺 (IFO) 1 2g/m2 静滴 ,d1～ 4,美司那 (Mesna) 40 0mg用IFO后 0、4、8h静推 ;依托泊甙 (VP 16) 65mg/m2 静滴 ,d1～ 4;强的松 (PRED) 10 0mg口服 ,d1～ 5。 2 1～ 2 8天为一周期 ,至少 3个周期。结果　MIEP方案化疗的疗效CR 2 8 6% ,PR 3 7 1% ,总有效率 65 7%。中位生存期为 19个月。毒副作用主要为骨髓抑制 ,白细胞减少发生率为 10 0 % ,其中Ⅲ度、Ⅳ度发生率为 71 4%。结论　MIEP方案治疗复发或难治非霍奇金淋巴瘤有效率高 ,毒性反应可耐受。     

子宫颈鳞癌ⅠA_1期30例临床分析

背景与目的:宫颈鳞癌ⅠA1期术前诊断和处理仍有争议,本研究旨在探讨ⅠA1期宫颈鳞癌诊断和处理的恰当方式。方法:回顾分析我院1992～2001年收治的30例宫颈鳞癌ⅠA1期患者的临床和病理资料。结果:30例患者中7例既无症状又无明显体征(23.3%)。23例行细胞学检查,阳性率为86.9%(20/23);23例行阴道镜检查,准确率为78.2%(18/23);10例行宫颈管刮取术,4例阳性。30例患者中22例行广泛或次广泛全子宫切除术(73.3%),6例行全子宫切除术,2例行宫颈冷刀锥切术;28例子宫切除标本宫旁组织均未受侵,阴道残端均无癌残留,其中8例行盆腔淋巴结清扫术,平均切除淋巴结22枚,均为阴性,两例锥切标本切缘干净;术前诊断与最后诊断符合率为56.7%(17/30)。术后中位随访时间34个月(17～111个月),均无复发。结论:ⅠA1期宫颈鳞癌术前阴道镜检查及宫颈多点活检诊断准确率低;冷刀锥切可提高诊断准确率,同时又可作为要求保留生育功能的ⅠA1期宫颈鳞癌患者的治疗方式。     

高场强电磁脉冲对Jurkat细胞IFN-γ和IL-4蛋白表达的定量分析

目的 :研究电磁脉冲 (EMP)辐照对白血病肿瘤细胞株Jurkat细胞分泌细胞因子IFN -γ和IL - 4的影响 ,探讨EMP对Jurkat细胞损伤机制。方法 :Jurkat细胞经EMP照射后即刻、1h、 6h、 12h、 2 4h、 4 8h、 72h共 7个时相点 ,细胞悬液甩片 ,4 %多聚甲醛 4℃固定 ,自然晾干 ,进行SP法的IFN -γ和IL - 4蛋白免疫组化染色。在光镜 10× 4 0倍视野下 ,应用CMIAS-H图像分析仪对阳性细胞的图像分析参数积分光密度值 (IOD)进行统计分析。结果 :免疫组化结果表明 ,场强 6× 10 4 V/m的电磁脉冲能使Jurkat细胞IFN -r表达持续性减少 ,差异非常显著 (P <0 0 1) ,而IL - 4变化不明显 (P >0 0 5 )。结论 :EMP辐照后Th1型的细胞因子IFN-γ明显减少 ,而Th2型的细胞因子IL - 4未见显著变化 ,提示 :EMP辐照后机体中受到影响的主要是细胞免疫 ,而体液免疫功能未受到明显影响     

一种基于多门限二进制编码的多光谱图像分类新方法

不同类型的地物具有不同的反射光谱 ,在多维光谱空间中构成不同的特征向量 ,这便是遥感多光谱图象分析与识别的物理依据。传统方法中有基于单个象元波段亮度的、空间纹理的、变换空间的多光谱图象特征提取与分析方法 ,但这些方法并没有直接描述地物的最本质特征———反射光谱曲线 ,从上个世纪 80年代开始 ,当二进制编码的方法提出并在多光谱匹配识别中获得成功应用后 ,多光谱图象分析处理便可以在这种特征提取的基础上 ,研究新的方法。本文提出一种基于光谱形状描述的多门限的二进制编码分类方法 ,并给出了图象实验的结果。     

CLINICAL ANALYSIS OF EXTRAMAMMARY PAGET’S DISEASE OF VULVA

Paget'sdiseasewasfirstlydescribedbyJamesPagetin1874asabreastlesion.ItwasalsoseenatotherplacesandgenerallycalledextramammaryPagetsdisease,76%ofwhichwaspredominantlyfoundonthevulva[1].Pagetsdiseaseofthevulvaremainsarareconditionthataccountsforlessthan1%ofvulvarneoplasms[2].Thelesionusuallyappearsaseczemaandmaybemisdiagnosed.However,invasivediseaseoradenocarcinomamaybepresentwithPagetsdisease.Andrecurrenceishighaftertreatment.TheaimofthisstudywastoreviewcasesofPagetsdiseaseinourhospitalandanal…     

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

PURPOSE: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy (RT) in unresectable head and neck cancer patients. Secondary end points were the measurement of h-R3 serum levels and the assessment of the potential mechanisms of antitumor effect on patient biopsies. Anti-idiotypic response to h-R3 was assessed. To predict pharmacologic effect, a mathematical model for antibodies recognizing antigens expressed in tumors and normal tissues was built. PATIENTS AND METHODS: Twenty-four patients with advanced carcinomas of the head and neck received six once-weekly infusions of h-R3 at four dose levels in combination with RT. Pretreatment tumor biopsies were obtained to evaluate epidermal growth factor receptor expression as an enrollment criterion. Second biopsies were taken to evaluate the proliferative activity and angiogenesis in comparison with the pretreatment samples. Patient serum samples were collected to measure h-R3 levels and anti-idiotypic response. RESULTS: The combination of h-R3 and RT was well tolerated. Antibody-related adverse events consisted in infusion reactions. No skin or allergic toxicity appeared. Overall survival significantly increased after the use of the higher antibody doses. Immunohistochemistry studies of tumor specimens before and after treatment revealed that antitumor response correlated with antiproliferative and antiangiogenic effect. One patient developed antibodies to h-R3. The mathematical model predicted that the maximum difference between the area under the curve in tumors and normal tissues is reached when the antibody has intermediate affinity. CONCLUSION: h-R3 is a well-tolerated drug that may enhance radiocurability of unresectable head and neck neoplasms.     

Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication.

PURPOSE: Abnormalities of FHIT, a candidate tumor suppressor gene, have frequently been found in multiple malignancies, including head and neck squamous cell carcinoma (HNSCC). To define its role in HNSCC treated with surgery and postoperative radiotherapy (PORT), the Fhit protein expression status was investigated in 80 patients enrolled in a prospective Phase III clinical trial addressing the dose and fractionation regimen of PORT. EXPERIMENTAL DESIGN: Immunohistochemical staining of HNSCC tissue sections for Fhit expression was performed. The Fhit expression status was correlated with the clinicopathological characteristics and clinical course. The median follow-up duration was 4.9 years. RESULTS: Loss of Fhit expression was found in 52 of the 80 study patients (65%). There was not a significant association between Fhit expression and clinical characteristics. Patients whose tumor exhibited negative Fhit expression had a significantly worse 5-year overall survival duration [hazard ratio = 0.49; 95% confidence interval, 0.23-1.03; P = 0.05 (log-rank test)] than did those whose tumor exhibited positive Fhit expression. One third of the patients with a Fhit-negative tumor had distant metastasis during the follow-up period. Paradoxically, patients classified as high risk who had a Fhit-negative tumor experienced locoregional recurrence less often (18%) than did high-risk patients who had a Fhit-positive tumor (33%). CONCLUSIONS: Loss of Fhit expression is a poor prognostic indicator in patients with HNSCC. However, tumors lacking Fhit expression may be more sensitive to PORT and therefore more susceptible to locoregional control.     

Thl Bias in PBMC Induced by Large Scale Auto-CIK Infusion in Malignant Solid Tumor Patients in China

OBJECTIVE This article is to verify feasibility and validity of autologous cytokine-induced killer cell (Auto-CIK) treatment in solid malignancypatients.METHODS Amplification, phenotypic characteristics, cytokine secretion,antitumor cytotoxicity and clinical response to Auto-CIK derived from 65cases of solid tumor patients with different pathological types and clinicalstages were compared with LAKs in a large-scale clinical trial,RESUL‘r$ We found that seriousness of disease and metastatic status hadno influence on effective components and antitumor immunological activityof Auto-ClK. Comparing cytotoxicity against various tumor cells with LAKsat various effector to target ratios, ClKs showed more effective cytotoxicityagainst NK sensitive or non-sensitive solid tumor cell lines at a low E/T ratio(6:1) which suggests indirectly that Auto-CIK had a longer effective time invivo than LAKs. These results suggest that CIKs are more suitable forimmunotherapy for those solid malignancy patients at high risk of relapse orrecurrence.CONCLUSIONS Our experimental data were consistent ~ith the reportedconclusion that the potent antitumor activity of Auto-ClK mainly rooted in theCD4- part of CIKs, including CD3~CD56~ cells and CD8 ~ CTLs. The CD4~part of ClKs seemed to have no direct tumor lytic activity. The results indicatethat the special “Thl bias“ and enhanced cytotoxicity against K562 cellsoccurred in PBMCs after multicycles of Auto-ClK infusions suggesting theinduction of a “Thl shift“ and rectification of “Th2 dominance“ in PBMC afterAuto-CIK treatments.     

Clinical Application of Breast Fiberoptic Ductoscopy in 354 Cases with Abnormal Nipple Discharge

OBJECTIVE To use the breast duct endoscope for studying thepathological characteristics of breast-duct disease with nipple discharge,and offer methods that can improve diagnostic accuracy.METHODS A total of 354 patients with nipple discharge were examinedusing the fiberoptic duct endoscope (FVS-3000M). Ducts and theirbranches were investigated to define and locate the extent of intraductallesions. Core biopsies were taken of suspicious lesions and the findingswere analyzed retrospectively.RESULTS In cases of bloody and serosanguineous nipple discharge,72.3% were papilloma and papillomatosis, 5.2% duct cancer and 22.5%mammary duct ectasia and galactophoritis. In patients with watery nippledischarge, 56.0% were papilloma and papillomatosis, 8.0% were breastcancer and 5 patients without abnormal findings were regarded asnormal.CONCLUSION Fiberoptic duct endoscopy can accurately locate the siteand pathology of nipple discharge allowing the improvement in diagnosisof early breast cancer.     

Ability of a Specific ERK Signal-Pathway Inhibitor to Reverse P-Glycoprotein- Mediated Vincristine Resistance in Colon Cancer Cell Unes

OBJECTIVE To investigate the effect of a specific inhibitor PD098059 of the extracellular-signal regulated protein kinase (ERK) pathway on the P-glycoprotein (P-gp)-mediated resistance of colon cancer cell lines SW480/VCR and CoLo205NCR.METHODS SW480NCR and CoLo205NCR cells were generated byexposuring SW480 and CoLo205 cells to vincristine (VCR) (30 ng/ml) for 72h, which resulted in a comparatively higher level of P-gp expression.Western blotting was used to analyze P-gp, MRP, LRP, GST-‘rr and TOPOIIexpression after exposuring the SW480 and CoLo205 cells to VCR (30 ng/ml)for 72 hrs. P-gp and pERK1/2 expressions was analyzed in SW480NCR andCoLo205/VCR cells treated with or without the specific inhibitor of MEK,PD098059. The MTT assay was used to determine the susceptibility ofSW480NCR and CoLo205NCR cells to VCR, treated with or withoutPD098059.I~F.SULI“S The results showed that VCR induced a comparatively higher levelof P-gp expression in the cell lines, but not that of MRP, LRP, GST-n- orTOPOII. P-gp expression levels were depressed significantly in SW480/VCR and COLO205/VCR cells by the specific inhibitor of MEK, PD098059.The IC50 (248 19.6 and 215 10.7 ng/ml) to VCR of SW480/VCR andCoLo205/VCR cells exhibited a 2.16 and 2.03-fold higher resistancecompared to the negative control group (SW480 and CoLo205 cells)(115 15.6 and 106 11.9 ng/ml), but a 1.35 and 1.21 -fold higher resistance thanthe group treated with VCR (30 ng/ml) PD098059 (184 21.8 and 177 19.4 ng/ml).CONCLUSION This study shows that the expression of P-gp can beinduced by exposuring cells to VCR, and that this induction can be reversedby inhibiting the ERK signaling pathway at the point of MEK by its specificinhibitor, PD098059. The ERK signal-transduction pathway may play a rolein modulating mdrl expression in colon cancer.